SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) July 24, 2017
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
900 South Capital of Texas Highway, Las Cimas IV, Suite 150
(Address of principal executive offices, including zip code)
(Registrants telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|☐||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|☐||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|☐||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|☐||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|Item 7.01.||Regulation FD Disclosure.|
Investors and others should note that Savara Inc. (Savara, we or our) may announce material information about its finances, product candidates, clinical trials and other matters to its investors using its investor relations website (https://savarapharma.com/investors), SEC filings, press releases, public conference calls and webcasts. We use these channels, as well as social media, to communicate with our stockholders and the public about our company and other issues. It is possible that the information we post on our website and social media could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company to review the information we post on our investor relations website (referenced above) and any social media channels listed on our website from time to time.
In this regard, from time to time, we plan to post a blog message from our Chief Executive Officer (CEO) on our website. The first such blog post will appear tomorrow morning on our investor relations website at https://savarapharma.com/investors/ceo-blog/.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Date: July 24, 2017|| |
a Delaware corporation
Chief Financial Officer